Technical specification for diagnosis and treatment of long-term complications of renal transplantation (2019 edition)
-
摘要: 为了进一步规范肾移植远期并发症的诊断与治疗,中华医学会器官移植学分会组织器官移植学专家从心血管系统并发症、移植后肿瘤、中枢神经系统并发症、消化系统并发症、血液系统并发症、肾移植术后皮肤疾病等方面,制订本规范。
-
[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志, 2012, 40(5):353-367. DOI:10. 3760/cma.j.issn.0253-3758.2012.05.001.Branch of Cardiovascular Diseases of Chinese Medical Association, Editorial Committee of Chinese Journal of Cardiology. Guidelines for diagnosis and treatment of non-ST-segment elevation acute coronary syndrome[J]. Chin J Cardiol, 2012, 40(5):353-367. DOI: 10.3760/cma.j.issn.0253-3758.2012.05.001. [2] AMSTERDAM EA, WENGER NK, BRINDIS RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2014, 64(24):e139-e228. DOI: 10.1016/j.jacc.2014.09.017. [3] LEVINE GN, BATES ER, BITTL JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. J Thorac Cardiovasc Surg, 2016, 152(5):1243-1275. DOI: 10.1016/j.jtcvs.2016.07.044. [4] ROFFI M, PATRONO C, COLLET JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(3):267-315. DOI: 10.1093/eurheartj/ehv320. [5] DEVEREAUX PJ, XAVIER D, POGUE J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study[J]. Ann Intern Med, 2011, 154(8):523-528. DOI: 10.7326/0003-4819-154-8-201104190-00003. [6] IBANEZ B, JAMES S, AGEWALL S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. [7] KASISKE BL, MACLEAN JR, SNYDER JJ. Acute myocardial infarction and kidney transplantation[J]. J Am Soc Nephrol, 2006, 17(3):900-907. doi: 10.1681/ASN.2005090984 [8] LENTINE KL, BRENNAN DC, SCHNITZLER MA. Incidence and predictors of myocardial infarction after kidney transplantation[J]. J Am Soc Nephrol, 2005, 16(2):496-506. doi: 10.1681/ASN.2004070580 [9] KABORÉ R, HALLER MC, HARAMBAT J, et al. Risk prediction models for graft failure in kidney transplantation: a systematic review[J]. Nephrol Dial Transplant, 2017, 32(suppl 2):ii68-ii76. DOI: 10.1093/ndt/gfw405. [10] 朱有华, 石炳毅.肾脏移植手册[M].北京:人民卫生出版社, 2010. [11] 黎磊石.中国肾移植手册[M]. 2版.香港:华夏科学出版社, 2009. [12] XIAO D, CRAIG JC, CHAPMAN JR, et al. Donor cancer transmission in kidney transplantation: a systematic review[J]. Am J Transplant, 2013, 13(10):2645-2652. DOI: 10.1111/ajt.12430. [13] WONG G, TURNER RM, CHAPMAN JR, et al. Time on dialysis and cancer risk after kidney transplantation[J]. Transplantation, 2013, 95(1):114-121. DOI: 10.1097/TP.0b013e31827743b4. [14] MA MK, LIM WH, TURNER RM, et al. The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis[J]. Transplantation, 2014, 98(12):1286-1293. DOI: 10.1097/TP.0000000000000375. [15] VAN LEEUWEN MT, WEBSTER AC, MCCREDIE MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study[J]. BMJ, 2010, 340:c570. DOI: 10.1136/bmj.c570. [16] HIBBERD AD, TREVILLIAN PR, WLODARCZYK JH, et al. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study[J]. Transplantation, 2013, 95(1):122-127. DOI: 10.1097/TP.0b013e3182782f59. [17] ABEDINI S, HOLME I, FELLSTRÖM B, et al. Cerebrovascular events in renal transplant recipients[J]. Transplantation, 2009, 87(1):112-117. DOI: 10.1097/TP.0b013e31818bfce8. [18] KUMAR S, DE LUSIGNAN S, MCGOVERN A, et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care[J]. BMJ, 2018, 360:k342. DOI: 10.1136/bmj.k342. [19] FINDLAY M, MACISAAC R, MACLEOD MJ, et al. Renal replacement modality and stroke risk in end-stage renal disease-a national registry study[J]. Nephrol Dial Transplant, 2018, 33(9):1564-1571. DOI: 10.1093/ndt/gfx291. [20] PIZZI M, NG L. Neurologic complications of solid organ transplantation[J]. Neurol Clin, 2017, 35(4):809-823. DOI: 10.1016/j.ncl.2017.06.013. [21] 中华医学会器官移植学分会.器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J].器官移植, 2019, 10(2): 149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006.Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for EB virus infection and posttransplant lymphoproliferative disease on recipients with organ transplantation in China (2019 edition)[J]. Organ Transplant, 2019, 10(2): 149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006. [22] ARNOLD R, PUSSELL BA, PIANTA TJ, et al. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients[J]. Am J Transplant, 2013, 13(9):2426-2432. DOI: 10.1111/ajt.12324. [23] COLES A. Neurologic complications in organ transplant recipients[J]. J Neurol Neurosurg Psychiatry, 2000, 68(1):123. DOI: 10.1136/jnnp.68.1.123c. [24] CIRIACO M, VENTRICE P, RUSSO G, et al. Corticosteroid-related central nervous system side effects[J]. J Pharmacol Pharmacother, 2013, 4(Suppl 1): S94-S98. DOI: 10.4103/0976-500X.120975. [25] FURUKAWA M, TERAE S, CHU BC, et al. MRI in seven cases of tacrolimus (FK-506) encephalopathy: utility of FLAIR and diffusion-weighted imaging[J]. Neuroradiology, 2001, 43(8):615-621. doi: 10.1007/s002340100545 [26] GAUTAM A. Gastrointestinal complications following transplantation[J]. Surg Clin North Am, 2006, 86(5):1195-1206, vii. doi: 10.1016/j.suc.2006.06.006 [27] SEN A, CALLISEN H, LIBRICZ S, et al. Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal[J]. Crit Care Clin, 2019, 35(1): 169-186. DOI: 10.1016/j.ccc.2018.08.011. [28] LUCAN VC, BERARDINELLI L. Gastrointestinal side effects of post-transplant therapy[J]. J Gastrointestin Liver Dis, 2016, 25(3):367-373. DOI: 10.15403/jgld. 2014.1121.253.ptt. [29] SU VCH, GREANYA ED, ENSOM MH. Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: a systematic review[J]. Ann Pharmacother, 2011, 45(2):248-257. DOI: 10.1345/aph.1P456. [30] DAVIES NM, GRINYÓ J, HEADING R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal[J]. Nephrol Dial Transplant, 2007, 22(9):2440-2448. doi: 10.1093/ndt/gfm308 [31] ROUSE GE, HARDINGER K, TSAPEPAS D, et al. A comparison of histamine receptor antagonists versus proton pump inhibitor gastrointestinal ulcer prophylaxis in kidney transplant recipients[J]. Prog Transplant, 2017, 27(1):4-9. DOI: 10.1177/1526924816669725. [32] GUO YW, GU HY, ABASSA KK, et al. Successful treatment of ileal ulcers caused by immunosuppressants in two organ transplant recipients[J]. World J Gastroenterol, 2016, 22(24):5616-5622. DOI: 10.3748/wjg.v22.i24.5616. [33] 中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年, 西安)[J].中华消化杂志, 2016, 36(8):508-513. DOI:10. 3760/cma.j.issn.0254-1432.2016.08.003.Editorial Committee of Chinese Journal of Digestion. Specification for diagnosis and treatment of peptic ulcer (Xi' an, 2016)[J]. Chin J Digest, 2016, 36(8):508-513. DOI: 10.3760/cma.j.issn.0254-1432.2016.08.003. [34] MALYSZKO J, OBERBAUER R, WATSCHINGER B. Anemia and erythrocytosis in patients after kidney transplantation[J]. Transpl Int, 2012, 25(10):1013-1023. DOI: 10.1111/j.1432-2277.2012.01513.x [35] REINDL-SCHWAIGHOFER R, OBERBAUER R. Blood disorders after kidney transplantation[J]. Transplant Rev (Orlando), 2014, 28(2):63-75. DOI: 10.1016/j.trre. 2013.10.001. [36] MUIRHEAD N. Erythropoietin and renal transplantation[J]. Kidney Int Suppl, 1999, 69:S86-S92. http://d.old.wanfangdata.com.cn/Periodical/dsjydxxb200404016 [37] CAMPISTOL JM, SCHENA FP. Kaposi' s sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors[J]. Nephrol Dial Transplant, 2007, 22(Suppl 1):i17- i 22. http://cn.bing.com/academic/profile?id=e71b6d7585c8e1aadd57e87089d29758&encoded=0&v=paper_preview&mkt=zh-cn [38] DRENO B. Skin cancers after transplantation[J]. Nephrol Dial Transplant, 2003, 18(6):1052-1058. doi: 10.1093/ndt/gfg023 [39] PONTICELLI C, CUCCHIARI D, BENCINI P. Skin cancer in kidney transplant recipients[J]. J Nephrol, 2014, 27(4):385-394. DOI: 10.1007/s40620-014-0098-4. [40] HOSSEINI-MOGHADDAM SM, SOLEIMANIRAHBAR A, MAZZULLI T, et al. Post renal transplantation Kaposi' s sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy[J]. Transpl Infect Dis, 2012, 14(4):338-345. DOI: 10.1111/j.1399-3062.2011.00714.x. [41] STOFF B, SALISBURY C, PARKER D, et al. Dermatopathology of skin cancer in solid organ transplant recipients[J]. Transplant Rev (Orlando), 2010, 24(4):172-189. DOI: 10.1016/j.trre.2010.05.002.
点击查看大图
计量
- 文章访问数: 596
- HTML全文浏览量: 273
- PDF下载量: 195
- 被引次数: 0